Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia
GSK responded to the released Senate Committee on Finance January 2010 Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia.
-
GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia
The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone).
-
GSK rejects conclusions reported in The New York Times story on Avandia
GlaxoSmithKline (GSK) rejects the conclusions about the safety of Avandia (rosiglitazone) reported in New York Times story.
-
GSK receives positive opinions in Europe for Tyverb® (lapatinib) and Votrient™ (pazopanib)
GSK announced today that CHMP has issued two positive opinions in the European Union for two of its cancer medicines.
-
GSK statement on FDA’s proposed label revisions for some asthma medicines
GSK is reviewing label changes proposed today by FDA for asthma medications containing long-acting beta-agonists (LABAs).
-
GSK Consumer Healthcare warns consumers of potential health risks associated with long-term excessive use of zinc-containing denture adhesives
Because the safety and health of our consumers is our primary concern.
-
GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant™ (GSK1838262/XP13512) for RLS
GSK and XNPT received a Complete Response letter from FDA regarding NDA for gabapentin enacarbil) Extended-Release Tablets.
-
GSK launches new specialist unit to research and develop medicines for rare diseases
GSK today announces the formation of a new standalone unit specialising in the development and commercialisation of medicines.
-
GSK announces appointment of Philippe Fauchet as President of GSK Japan
GSK today announces the appointment of Philippe Fauchet as President of GSK Japan.
-
Results announcement for the fourth quarter 2009
See the quarterly results page for more information
-
GSK’s Tykerb® receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer
GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval.
-
Rotarix™ significantly reduced severe rotavirus gastroenteritis in African babies during their first year of life
NEJM today published the first study demonstrating that Rotarix, GSK rotavirus vaccine.
-
GSK announces ‘open innovation’ strategy to help deliver new and better medicines for people living in the world’s poorest countries
'Open Lab' established with $8m seed funding for new research
-
GSK contributes to Haiti relief efforts
In keeping with GSK's response to previous natural disasters, we have initiated a program of support for Haiti.
-
GSK exercises option to progress development of ChemoCentryx’s Traficet-EN for the treatment of inflammatory bowel diseases
GlaxoSmithKline(GSK) andChemoCentryx Inc. today announced that GSK has exercised its option to obtain an exclusive license.
-
Revolade (eltrombopag) receives positive opinion in Europe for chronic immune thrombocytopenic purpura
GSK announced today that CHMP has issued a positive opinion for Revolade.
-
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
Next advance in the treatment of cold sores - Strengthens a key OTC franchise
-
GSK publishes speaking, consulting fees paid to US healthcare professionals
Company progresses commitments to increase transparency
-
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated.
-
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
GlaxoSmithKline Biologicals SA (GSK) and Intercell today announced an agreement to form a strategic alliance to accelerate the development.